Environmental Epigenetics: Crossroad between Public Health, Lifestyle, and Cancer Prevention

Table 2

Epigenetic modifier drugs in noncancer clinical trials (partial list).

Drug	Disease	NCT number	Phase
5-Azacitidine	Beta thalassemia	NCT00005934	Phase 2
5-Azacytidine + Na phenylbutyrate	Thalassemia major	NCT00007072	Phase 2
Resveratrol	Cardiovascular diseases	NCT01449110	Phase 2
Resveratrol	Trauma	NCT01321151	Phase 1
Resveratrol	Metabolic syndrome, obesity	NCT01150955	Phase 1
Curcumin	Irritable bowel syndrome	NCT00779493	Phase 4
Curcumin	Alzheimer disease	NCT00164749	Phase 2
Curcumin	Psoriasis	NCT00235625	Phase 2